Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Total Current Liabilities (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Total Current Liabilities readings, the most recent being $7.2 million for Q4 2022.

  • On a quarterly basis, Total Current Liabilities fell 21.28% to $7.2 million in Q4 2022 year-over-year; TTM through Dec 2022 was $7.2 million, a 21.28% decrease, with the full-year FY2022 number at $7.2 million, down 21.28% from a year prior.
  • Total Current Liabilities hit $7.2 million in Q4 2022 for Cardiol Therapeutics, down from $7.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $9.2 million in Q4 2021 to a low of $1.9 million in Q4 2020.
  • Median Total Current Liabilities over the past 3 years was $7.3 million (2022), compared with a mean of $5.9 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 375.0% in 2021 and later dropped 21.28% in 2022.
  • Cardiol Therapeutics' Total Current Liabilities stood at $1.9 million in 2020, then surged by 375.0% to $9.2 million in 2021, then fell by 21.28% to $7.2 million in 2022.
  • The last three reported values for Total Current Liabilities were $7.2 million (Q4 2022), $7.4 million (Q3 2022), and $8.9 million (Q2 2022) per Business Quant data.